Insider Buying: CSL (ASX:CSL) Insider Acquires A$65,625.05 in Stock

CSL Limited (ASX:CSL) insider Brian McNamee acquired 433 shares of CSL stock in a transaction on Tuesday, February 17th. The stock was purchased at an average cost of A$151.56 per share, for a total transaction of A$65,625.05.

CSL Stock Performance

The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68. The firm has a market capitalization of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32.

CSL Dividend Announcement

The firm also recently declared a Interim dividend, which will be paid on Wednesday, April 8th. Investors of record on Wednesday, April 8th will be issued a $1.837 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a dividend yield of 121.0%. CSL’s dividend payout ratio (DPR) is presently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.